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The majority of triple-negative breast cancers (TNBCs) are basal-like breast cancers. However there is no reported
study on anti-tumor effects of sunitinib in xenografts of basal-like TNBC (MDA-MB-468) cells. In the present study,
MDA-MB-231, MDA-MB-468, MCF-7 cells were cultured using RPMI 1640 media with 10% FBS. Vascular endothelia
growth factor (VEGF) protein levels were detected using ELISA (R & D Systams). MDA-MB-468 cells were exposed to
sunitinib for 18 hours for measuring proliferation (3H-thymidine incorporation), migration (BD Invasion Chamber),
and apoptosis (ApopTag and ApoScreen Anuexin V Kit). The effect of sunitinib on Notch-1 expression was
determined by Western blot in cultured MDA-MB-468 cells. 106 MDA-MB-468 cells were inoculated into the left
fourth mammary gland fat pad in athymic nude-foxn1 mice. When the tumor volume reached 100 mm3,
sunitinib was given by gavage at 80 mg/kg/2 days for 4 weeks. Tumor angiogenesis was determined by CD31
immunohistochemistry. Breast cancer stem cells (CSCs) isolated from the tumors were determined by flow
cytometry analysis using CD44+/CD24− or low. ELISA indicated that VEGF was much more highly expressed in
MDA-MB-468 cells than MDA-MB-231 and MCF-7 cells. Sunitinib significantly inhibited the proliferation, invasion,
and apoptosis resistance in cultured basal like breast cancer cells. Sunitinib significantly increased the expression of
Notch-1 protein in cultured MDA-MB-468 or MDA-MB-231 cells. The xenograft models showed that oral sunitinib
significantly reduced the tumor volume of TNBCs in association with the inhibition of tumor angiogeneisis, but
increased breast CSCs. These findings support the hypothesis that the possibility should be considered of sunitinib
increasing breast CSCs though it inhibits TNBC tumor angiogenesis and growth/progression, and that effects of
sunitinib on Notch expression and hypoxia may increase breast cancer stem cells. This work provides the
groundwork for an innovative therapeutic strategy in TNBC therapy by using sunitinib plus γ-secretase inhibitor
to simultaneously target angiogenesis and CSC.
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Triple-negative breast cancer (TNBC) refers to any breast
cancer that does not express the genes for estrogen recep-
tor (ER), progesterone receptor (PR) and Her2/neu [1].
TNBC accounts for >15% of breast cancer [2], and 39% in
African American premenopausal women with breast can-
cer [3]. TNBCs exhibit a high level of molecular hetero-
geneity, and are biologically aggressive: a poor prognostic
factor for disease-free and overall survival in the adjuvant
and neoadjuvant setting, a more aggressive clinical course
in the metastatic setting, and no effective specific targeted
therapy [1,2]. TNBCs comprise the basal and claudin-low
molecular subtypes. The majority of TNBCs (approxi-
mately 80%) are basal-like breast cancers [4]. The signal-
transduction pathways involving vascular endothelial
growth factor receptor (VEGFR), platelet-derived growth
factor receptor (PDGFR), stem-cell factor receptor (KIT),
and colony stimulating factor-1 receptor (CSF-1R) have
been implicated in breast cancer pathogenesis [5-10].
VEGFR and KIT have shown to be associated with TNBCs
[10-13]. Sunitinib is an inhibitor of receptor tyrosine ki-
nases that include VEGFR, PDGFR, KIT, and CSF1R
[6,11,14]. We previously reported that sunitinib targeted
the paracrine and autocrine effects of VEGF on breast
cancer to suppress tumor angiogenesis, proliferation and
migration in a mouse ER-positive breast cancer model
[11]. There were several reports that sunitinib inhibited
tumor angiogenesis and tumor growth in xenografts of
the claudin-low TNBC (MDA-MB-231) cells [15-17]. In a
phase II study in patients with heavily pretreated meta-
static breast cancer, 15% of patients (three of 20) with
TNBC achieved partial responses following treatment
with single-agent sunitinib [18]. However, there is no re-
ported study on anti-tumor effects of sunitinib in xeno-
grafts of the basal-like TNBC (MDA-MB-468) cells.
Sunitinib has been used as anticancer treatments in
several tumor types including breast cancer [19], how-
ever clinical observations indicate this therapy may have
limited efficacy. When anti-angiogenic agents are admin-
istered on an intermittent schedule, such as with suniti-
nib (4 wk on, 2 wk off ), tumor regrowth is sometimes
seen during drug-free periods [18] or upon discontinu-
ation of the treatment [20]. Although anti-angiogenic
agents produce inhibition of primary tumor growth, last-
ing responses are rare, with only a moderate increases in
progression-free survival and little benefit in overall sur-
vival [21]. Anti-angiogenic agents generate intratumoral
hypoxia modulating the metastatic process [22] and
stimulating cancer stem cells (CSC) [23,24]. Cancer stem
cells (CSCs) are cells that have the ability to self-renew
and give rise to differentiated tumor cells, and constitute
a rare subpopulation in a tumor mass. CSCs are thought
to play a role in recurrence and metastasis of TNBC [25].
Various experiments support that the Notch pathway iscritical in controlling the fate of CSC in breast cancer
[25,26] and that anti-angiogenic therapy may actually acti-
vate Notch and preserve CSC [27]. It is therefore possible
that sunitinib may induce breast cancer CSC and activate
the Notch pathway.
We hypothesize that sunitinib can suppress basal-like
TNBC tumor angiogenesis and growth/progression via
inhibition of paracrine and autocrine effects of VEGF,
and that sunitinib-induced tumor hypoxia may increase
breast cancer stem cells. Thus, the present study aimed
to determine the following: 1) whether VEGF is highly
expressed in MDA-MB-468 cells, compared to MCF-7
and MDA-MB-231 cells; 2) whether sunitinib inhibits
the proliferation, migration, apoptosis resistance of cul-
tured MDA-MB-468 cells; 3) whether oral sunitinib treat-
ment suppresses tumor angiogenesis and growth in the
basal-like TNBC (MDA-MB-468) xenografts; 4) whether
sunitinib increases the percentage of breast cancer stem
cells in the xenografts; and 5) whether sunitinib increases
the expression of Notch-1 in MDA-MB-468 cells. The ef-
fects of sunitinib on claudin-low TNBC MDA-MB-231
xenografts and cell cultures were also tested.
Materials and methods
Chemicals and cell lines
Sunitinib was purchased from LC Laboratories (Woburn,
MA). Human estrogen-receptor positive breast cancer
(MCF-7) cells, human claudin-low triple-negative breast
cancer (MDA-MB-231) cells, and basal-like breast cancer
(MDA-MB-468) cells were purchased from the American
Type Culture Collection (Rockville, MD). All breast can-
cer cells were maintained as monolayer cultures in RPMI
Medium 1640 (GIBCO) supplemented with 10% FBS
(HyClone), 100 U/ml penicillin, 100 μg/ml streptomycin,
and 0.25 μg/ml amphotericin B, and incubated at 37°C in
a humidified 5% CO2/air injected atmosphere. Sunitinib
was suspended in vehicle containing carboxymethylcellu-
lose sodium (United States Pharmacopia; 0.5% wt/vol,
NaCl 1.8% wt/vol); Tween 80 0.4% wt/vol), benzyl alcohol
0.9% wt/vol), and deionized water adjusted to pH 6.0.
Sunibinib was prepared weekly and kept at 4°C.
Animal protocols
The protocols were carried out according to the guide-
lines for the care and use of laboratory animals imple-
mented by the National Institutes of Health and the
Guidelines of the Animal Welfare Act and were approved
by the University of Mississippi Medical Center’s Institu-
tional Animal Care and Use Committee. Eight female
athymic nude-Foxn1 mice at 10 weeks of age were pur-
chased from Harlan Laboratories (Indianapolis, IN). The
mice were allowed to acclimate for 2 weeks with standard
chow diet (Teklad, Harlan Sprague Dawley; Indianapolis,
IN) and tap water before beginning the experiments. The
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10^6 MDA-MB-468 cells suspended in 100 μl of
phosphate-buffered saline with matrigel (BD Bioscience,
Bedford, MA) into the left fourth mammary gland fat pad.
Two weeks after the inoculation, the tumor volume
reached around 100 mm3. Then 4 mice received sunitinib
given by gavage at 80 mg/kg/2 days for 4 weeks and other
4 mice received the vehicle only as the control group. For
MDA-MB-231 xenografts, the twelve week old female
mice (n = 8) were inoculated with 10^6 MDA-MB-231
cells into the left fourth mammary gland fat pad. When
the tumor volume reached around 500 mm3, four female
athymic nude-Foxn1 mice received sunitinib given by gav-
age at 80 mg/kg/2 days for 4 weeks and the other 4 mice
received the vehicle only as the control group. The body
weight of the mice was monitored weekly. Tumor size was
monitored every other day in two perpendicular dimen-
sions parallel with the surface of the mice using dial cali-
pers. At the end of the experiment, blood samples and
tumors were collected to measure VEGF expression using
ELISA and average microvascular density (AMVD) or ca-
pillary density (CD) using CD31 immunohistochemistry.
Morphometric analysis of angiogenesis in tumors
The quantification of blood vessels in the tumors of xe-
nografts with MDA-MB-468 cells or MDA-MB-231 cells
was determined with the modification of a previously re-
ported method [11,28]. Briefly, the tissues were fixed in
4% neutrally buffered paraformaldehyde. Consecutive
thin cryosections (5 μm) of OCT compound (Sakura
Finetek, Torrance, CA) embedded tissue samples were
fixed in acetone at 4°C for 10 min. After washing in
phosphate buffered saline (PBS), the sections were first
treated with 3% H2O2 for 10 minutes to block endogen-
ous peroxidase activity and then were blocked with nor-
mal rabbit serum. Next, the sections were washed in
PBS and incubated with rat anti-mouse CD31 (PECAM-1)
monoclonal antibody (BD Pharmingen, San Diego, CA)
at a 1:200 dilution overnight at 4°C. Negative controls
were incubated with the rat serum IgG at the same di-
lution. All sections were washed in PBS containing
0.05% Tween-20, and were then incubated with a 2nd
antibody, mouse anti-rat IgG (Vector laboratories,
Burlingame, CA) at a 1:200 dilution for 1 hour at room
temperature, again followed by washing with PBS contain-
ing 0.05% Tween-20. The sections were incubated in a
1:400 dilution of Extravadin Peroxidase (Sigma, St. Louis,
MO) for 30 min. After washing in PBS containing 0.05%
Tween-20, the sections were incubated in peroxidase
substrate (Vector laboratories, Burlingame, CA) for 5 min.
The sections were washed in PBS containing 0.05%
Tween-20 and were counterstained with hematoxylin. A
positive reaction was indicated by a brown staining. The
microvascular vessels or capillary density (CD) werequantified by manual counting under light microscopy.
A microscopic field (0.7884 mm2) was defined by a grid
laced in the eye-piece. At least 20 microscopic fields
were randomly acquired from each tumor for analysis.
Any endothelial cell or cell cluster showing antibody
staining and clearly separated from an adjacent cluster
was considered to be a single, countable microvessel or
capillary. The value of the average microvascular density
(AMVD) or capillary density (CD) was determined by
calculating the mean of the vascular counts per mm2 ob-
tained in the microscopic fields for each tissue sample.
Flow cytometry
The tumor cells in a single cell suspension were isolated
from the each xenograft within 2 hours by using the
gentleMACs Dissociator and Tumor Dissociation Kit
(Miltenyi Biotec Inc., Auburn, CA) according to the
manufacturer’s guidelines. 0.5 × 106 cells per sample for
flow cytometry analysis were as follows: a) unstained; b)
stained with mouse IgG1-PE/-FITC; c) stained with
anti-human CD44-PE; d) stained with anti-human CD24-
FITC; and e) stained with anti-human CD44-PE/CD24-
FITC (Miltenyi Biotec Inc., Auburn, CA). The fluorescence
intensity of these cell samples was analyzed by the Gallios
flow cytometer (Beckman Coulter, Inc., Brea, CA). The
ALDEFLUOR kit (Stemcell Technologies) was used for
the identification of cancer stem cells from MDA-MB-
231 xenografts by flow cytometry analysis.
Measurements of protein levels of VEGF by ELISA
Protein levels of VEGF in cultured MCF-7, MDA-MB-
231, and MDA-MB-468 cells were determined using mouse
VEGF ELISA kits (R & D Systems, Minneapolis, MN), ac-
cording to the manufacturer’s instructions. The total pro-
teins of cultured MCF-7, MDA-MB-231, or MDA-MB-468
cells were extracted using NE-PER Cytoplasmic Extraction
Reagents (Pierce, Rockford, IL), according to the manufac-
turer’s protocol. Protein levels of VEGF in these cells were
determined in the cultured media 18 hrs after the incuba-
tion. The total protein concentration of cultured MCF-7,
MDA-MB-231 or MDA-MB-468 cells was determined
using a Bio-Rad Protein Assay (Bio-Rad Laboratories,
Hercules, CA). The protein concentrations of VEGF were
normalized and expressed as pictograms per milligram of
total cellular protein.
Proliferation assay
The MDA-MB-468 or MDA-MB-231 cells were seeded
into 6-well tissue culture plates using RPMI Medium
1640 (GIBCO) supplemented with 10% FBS (HyClone),
100 U/ml penicillin, 100 μg/ml streptomycin, and
0.25 μg/ml amphotericin B, and incubated at 37°C in a
humidified 5% CO2/air injected atmosphere. When the
monolayer reached about 80% confluence, the cells were
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Medium 1640 with 10% FBS in the absence or presence
of sunitinib (0, 1, 5, or 10 μmol/L) for 18 hours. 3H-
thymidine incorporation assay was used to determine
the cell proliferation during the last 6 hours of incuba-
tion as previously described [29].
Migration assay
Migration was determined using BD BioCoat Matrigel
Invasion Chamber (BD Bioscience Discovery Labware,
Sedford, MA) according to a previous study, in which
only invasive cells digested the matrix and moved
through the insert membrane [29]. 1 × 105 MDA-MB-
468 cells per well in 0.5 ml RPMI Medium 1640 were
seeded in the matrigel-coated upper compartment (in-
sert) of a Transwell (24-well format, 8-μm pore) in the
absence or presence of sunitinib (1 μmol/L). Medium
with 10% FBS was added to the lower part of the well.
After overnight incubation at 37°C and 5% CO2, cells on
the upper surface of the insert were removed using a
cotton wool swab. Migrated cells on the lower surface of
the insert were stained using DiffQuit (Dada Behring,
Düdinen, Switzerland). Images of migrated cells were
taken and the number of migrated cells was counted
using a microscope (Leica, Germany) in a 20× objective.
Apoptosis assay
TUNEL staining was performed using the ApopTag
Peroxidase In Situ Apoptosis Detection Kit (Millipore)
according to the manufacturer’s instructions. Cultured
MDA-MB-468 cells were treated with Sunitinib (5 μmol/L)
or the vehicle only as the control group for 24 hours.
The cells were fixed in 10% neutral buffered forma-
lin and stained for DNA strand breaks associated
with apoptosis following the manufacturer’s instruc-
tions. The cells were counterstained with methyl green
(Vector Laboratories). The ApoScreen Anuexin V
Apoptosis Kit (Beckman Coulter) was also used to de-
tect apoptotic cells. Cultured MDA-MB-468 cells were
treated with Sunitinib (5 μmol/L) or the vehicle only
as the control group for 24 hours. The cells in single
cell suspensions were collected, stained with Anuexin
V-FITC, and analyzed by flow cytometry according to
the manufacturer’s guidelines.
Western blot
Cultured MDA-MB-468 or MDA-MB-231 cells were
treated with Sunitinib (0.1 and 1 μmol/L) or the vehicle
for 24, 48, and 72 hours. Western blot analysis was per-
formed as previously described [30]. Briefly, Whole cell
extracts were prepared by lysing cells in RIPA buffer
containing a mixture of protease and phosphatase inhibi-
tor cocktails (Thermo Scientific, Rockford, IL) followed by
sonication and centrifugation. Protein concentration wasdetermined using a Bradford Assay (BioRad Laboratories,
Hercules, CA). 50 μg of protein was loaded onto a 4-
20% gradient (SDS/PAGE) precast gel (BioRad Labora-
tories, Hercules, CA), transferred to a nitrocellulose
membranes, and blocked with Odyssey blocking buffer
(LI-COR Biosciences, Lincoln, NE). The membranes
was then incubated anti-Notch-1 (C-20) antibody (Santa
Cruz Biotechnology) (1:500) dilution in 10 ml of block-
ing buffer containing 0.15% Tween 20, and washed with
PBST buffer containing 0.1% Tween 20. IRdye 680 sec-
ondary antibodies were used to visualize and quantify
the protein bands by an Odyssey scanner (LI-COR Biosci-
ences, Lincoln, NE). β-actin expression (Sigma-Aldrich)
was evaluated as a control for protein loading. Differences
in protein expression were determined by densitometry
analysis using ImageJ Software (National Institutes of
Health, USA).
Statistical analysis
All determinations were performed in duplicated sets.
Where indicated, data is presented as mean ± SE. Statis-
tically significant differences in mean values between the
two groups were tested by an unpaired Student’s t-test.
Linear regression was performed by the correlation ana-
lysis between two continuous variables. A value of P <
0.05 was considered statistically significant. All statistical
calculations were performed using SPSS software (SPSS
Inc., Chicago, IL).
Results
Oral administration of sunitinib suppresses the
progression of TNBC tumor growth in nude mice
When the tumor volume reached around 100 mm3 in
the basal-like TNBC (MDA-MB-468) xenografts, four fe-
male athymic nude-Foxn1 mice received sunitinib given
by gavage at 80 mg/kg/2 days for 4 weeks and the other
4 mice received the vehicle only as the control group.
On the day 4 of treatment, the tumor volume was signifi-
cantly reduced by 32.9% (p < 0.01) in the sunitinib-treated
group in contrast to the control group (Figure 1A). At the
conclusion of the experiment, the tumor volume was sig-
nificantly reduced by 90.4% (p < 0.01) in the sunitinib-
treated group in contrast to the control group (Figure 1A),
which was consistent with the reduction in tumor weight
in the sunitinib-treated group compared to the control
group (31 ± 0.6 vs. 294 ± 28 mg; P <0.01). For MDA-MB-
231 xenografts, when the tumor volume reached around
500 mm3, four female athymic nude-Foxn1 mice received
sunitinib given by gavage at 80 mg/kg/2 days for 4 weeks
and the other 4 mice received the vehicle only as the
control group. In the end, the tumor volume was signifi-
cantly reduced by 94% (p < 0.01; n = 4) in the sunitinib-
treated group in contrast to the control group (Figure 2).
Clearly, oral sunitinib at 80 mg/kg/2 days for 4 weeks
Figure 1 Sunitinib treatment significantly inhibited tumor growth and tumor angiogenesis of the basal-like triple-negative breast cancer.
Oral sunitinib significantly suppressed the basal-like TNBC growth curve of tumor volume in MDA-MB-468/xenografts (A). When the tumor volume
reached around 100 mm3, four female athymic nude-Foxn1 mice received sunitinib given by gavage at 80 mg/kg/2 days for 4 weeks and the other 4
mice received the vehicle only as the control group. At the conclusion of the experiment, the tumor volume was significantly reduced by 90.4%
(p < 0.01; n = 4) in the sunitinib-treated group in contrast to the control group, which was consistent with the reduction in tumor weight in the
sunitinib-treated group compared to the control group (31 ± 0.6 vs. 294 ± 28 mg; P <0.01). The digital images of CD31 staining of the basal-like
TNBC tumors showed that the sunitinib-treated tumor had fewer microvessels than the control tumor (B). Morphometric analysis (B) indicated that
sunitinib- treatment caused a significant decrease in average microvessel density (the number of microvessels per mm2 area) of the basal-like TNBC
tumors when compared to the control tumors (72 ± 8 vs. 114 ± 10 microvessels number per mm2; n = 4; p < 0.01).
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like TNBC (MDA-MB-468) or the claudin-low TNBC
(MDA-MB-231) xenografts.
Sunitinib-treatment inhibits tumor angiogenesis of the
basal-like or clauding-low TNBC in mice
Growth and expansion of tumor mass is mainly dependent
on angiogenesis because neovascularization contributes
rapid tumor growth by providing an exchange of nutri-
ents, oxygen and paracrine stimulus of the tumor. There-
fore, in this study, we used a morphometric analysis of
immunohistochemical staining for CD31 to determine the
effect of sunitinib on tumor angiogenesis of the basal-like
TNBC. Representative images of CD31 staining of the
breast cancer tumors showed that the sunitinib-treated
tumor had fewer microvessels than the control tumor
(Figure 1B). Morphometric analysis (Figure 1B) indicated
that sunitinib treatment caused a significant decrease in
average microvessel density (the number of microvessels
per mm2 area) of the basal-like TNBC tumors when com-
pared to the control tumors (72 ± 8 vs. 114 ± 10 microves-
sels number per mm2; n = 4; p < 0.01). For MDA-MB-231
xenografts (Figure 2), sunitinib- treatment caused a signifi-
cant decrease in average microvessel density (the number
of microvessels per mm2 area) of the claudin-low TNBC
tumors when compared to the control tumors (68 ± 9 vs.
125 ± 16 microvessels number per mm2; n = 4; p < 0.01).
These results suggest that the pronounced decrease intumor angiogenesis is associated with the decrease in
tumor size found in the sunitinib treated groups compared
to those in the control groups.
VEGF expression is higher in the basal-like TNBC
(MDA-MB-468) than MDA-MB-231and MCF-7 cells
VEGF is involved in promoting breast cancer progres-
sion [11,31]. VEGF and its receptors are expressed in
MCF-7 and MDA-MB-231 cells [11,32], however, it has
not been reported whether VEGF is expressed differen-
tially in MDA-MB-468, MDA-MB-231 and MCF-7 cells.
We examined the expression of VEGF protein in cul-
tured MDA-MB-468, MDA-MB-231 and MCF-7 cells
using ELISA assay. Figure 3A shows that VEGF protein
is expressed more in MDA-MB-468 cells than MDA-
MB-231 cells (>3 fold, P < 0.01, n = 6; 10257 ± 212 vs.
3408 ± 136 pg/mg) or MCF-7 cells (>30 fold, P < 0.01,
n = 6; 10257 ± 212 vs. 336 ± 15 pg/mg). Clearly, VEGF
expression in TNBC cells is much higher than estrogen
receptor positive cells (MCF-7). These results may sug-
gest that VEGF in breast cancer could be biological
marker for breast cancer prognosis and progression.
Sunitinib suppresses the proliferation of cultured
MDA-MB-468 or MDA-MB-231 cells
We used a 3H-thymidine incorporation assay to deter-
mine the effects of sunitinib on the proliferation of cul-
tured MDA-MB-468 cells. Figure 3B shows that treating
BA
C
Figure 2 Sunitinib treatment significantly inhibited tumor growth, tumor angiogenesis, and the proliferation of the claudin-low triple
negative breast cancer. Oral sunitinib at 80 mg/kg/2 days for 4 weeks significantly suppressed the claudin-low TNBC growth curve of tumor
volume (A) and tumor angiogenesis (B) in MDA-MB-231/xenografts. When the tumor volume reached around 500 mm3, four female athymic
nude-Foxn1 mice received sunitinib given by gavage at 80 mg/kg/2 days for 4 weeks and the other 4 mice received the vehicle only as the
control group. In the end, the tumor volume was significantly reduced by 94% (P < 0.01; n = 4) in the sunitinib-treated group in contrast to the
control group, which was consistent with the inhibition of tumor angiogenesis (B). Sunitinib- treatment caused a significant decrease in average
microvessel density (the number of microvessels per mm2 area) of the claudin-low TNBC tumors when compared to the control tumors (68 ± 9
vs. 125 ± 16 microvessels number per mm2; n = 4; p < 0.01). 3H-thymidine incorporation assay indicated that sunitinib-treatment caused a
dose-related inhibition on proliferation in cultured MDA-MB-231 cells, by 23% at 1 μmol/L, by 40% at 5 μmol/L, and 55% at 10 μmol/L, compared
to the control group (n = 6; P < 0.01), respectively (C).
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decrease in 3H-thymidine incorporation, decreasing by
24% at 1 μmol/L, by 41% at 5 μmol/L, and 59% at
10 μmol/L, compared to the control group (n = 6; P <
0.01), respectively. Also, sunitinib-treatment caused a
dose-related inhibition on proliferation in cultured
MDA-MB-231 cells, by 23% at 1 μmol/L, by 40% at
5 μmol/L, and 55% at 10 μmol/L, compared to the con-
trol group (n = 6; P < 0.01), respectively (Figure 2C). The
findings suggest that sunitinib can inhibit proliferation
by directly targeting the basal-like or claudin-low TNBC
cells.Sunitinib directly inhibits migration and increases
apoptosis of cultured MDA-MB-468 cells
We examined the inhibitory effect of sunitinib on MDA-
MB-468 cell migration using BD BioCoat Matrigel Inva-
sion Chamber. Figure 4A demonstrated that sunitinib at
1 μmol/L significantly inhibited the invasion of MDA-
MB-468 cells by 45% compared to the control (n = 6;
P < 0.01). In the another experiment, as shown in Figure 4B,
we demonstrated that sunitinib at 5 μmol/L significantly
increased apoptosis of cultured MDA-MB-468 cells, in
which increased TUNEL staining (Figure 3B images)
and Anuexin V-positive cells were observed in sunitinib-
AB
Figure 3 VEGF protein was highly expressed in cultured
MDA-MB-468 cells in which sunitinib-treatment caused a
dose-related inhibition on the proliferation. Figure A showed
that VEGF protein was more expressed in MDA-MB-468 cells than
MDA-MB-231 cells (>3 fold, P < 0.01, n = 6; 10257 ± 212 vs. 3408 ±
136 pg/mg) or MCF-7 cells (>30 fold, P < 0.01, n = 6; 10257 ± 212
vs. 336 ± 15 pg/mg). 3H-thymidine incorporation assay indicated
that sunitinib-treatment caused a dose-related inhibition on
proliferation in cultured MDA-MB-468 cells, by 24% at 1 μmol/L,
by 41% at 5 μmol/L, and 59% at 10 μmol/L, compared to the control
group (n = 6; P < 0.01), respectively (B).
Figure 4 Sunitinib at 1 μmol/L significantly inhibited the invasion of M
Invasion Chamber, compared to the control group (34 ± 4 vs. 61 ± 8 c
MDA-MB-468 cells (A) (B) indicated that sunitinib at 5 μmol/L significantly
TUNEL staining of sunitinib-treated or the control MDA-MB-468 cells. Anue
to the control group (19.4% vs. 4.4% of Anuexin V-positive cells; n = 6; P < 0
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4.4% of Anuexin V-positive cells; n = 6; P < 0.01), respect-
ively. These results suggest that sunitinib can directly tar-
get the basal-like TNBC cells to inhibit migration and
increase apoptosis.Sunitinib-treatment in vivo significantly increases the
percentage of breast cancer stem cells in the basal-like or
claudin-low TNBC
To determine whether sunitinib stimulates an increase in
breast cancer stem cells in vivo, the tumor cells in a single
cell suspension were isolated from the each tumor in the
sunitinib-treated or the control MDA-MB-468/xenografts
4 weeks after the treatment. Flow cytometry analysis of
the tumor cells stained with anti-human CD44-PE/CD24-
FITC indicated that sunitinib treatment in vivo signifi-
cantly increased the percentage of breast cancer stem cells
(CD44+/CD24- or low) in basal like breast cancer (MDA-
MB-468) in athymic nude-foxn1 mice (3.6 ± 0.3% vs. 6.4 ±
0.5%; n = 4; P < 0.01) as shown in Figure 5. Treatment with
sunitinib for 28 days initiated after MDA-MB-231 tumors
reached around 500 mm3 significantly increased the per-
centage of Aldefluor-positive tumor cells (breast CSCs),
by 2.3-fold compared to the control group (3.4 ± 0.8% vs.
1.5 ± 0.7%; P < 0.01; N = 4). The results of sunitinib on
MDA-MB-231xenografts were consistent with the previ-
ous report by Conley SJ et al. [17]. These findings suggest
that sunitinib increases breast cancer stem cells in TNBC
in vivo.DA-MB-468 cells invasion or migration in BD BioCoat Matrigel
ell number/mm2; P < 0.01; n = 6). The images showed the migrated
increased apoptosis of cultured MDA-MB-468 cells. The images were
xin V-positive cells were observed in sunitinib-treated group, compared
.01), respectively.
Figure 5 Flow cytometry analysis of the tumor cells stained with anti-human CD44-PE/CD24-FITC indicated that sunitinib treatment in vivo
significantly increased the percentage of breast cancer stem cells (CD44+/CD24- or low) in basal like breast cancer (MDA-MB-468) in
athymic nude-foxn1 mice (3.6 ± 0.3% vs. 6.4 ± 0.5%; n = 4; P < 0.01).
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cultured MDA-MB-468 or MDA-MB-231 cells
Notch signaling has been proposed to maintain the
stemness of breast cancer stem cells [25,26]. Elevated
Notch-1 in human breast cancer is associated with poor
clinical outcomes [33]. To determine the possible mech-
anisms of sunitinib-induced the stemness of breast can-
cer stem cells, we used Western blot for examining
whether sunitinib increases the expression of Notch1 in
cultured MDA-MB-468 cells. Cultured MDA-MB-468
cells were treated with sunitinib (0.1 and 1 μmol/L) or the
vehicle for 24, 48, and 72 hours. Sunitinib at 0.1 μmol/L
did not significantly increase the expression of Notch-1 at
24, 48, and 72 hours of the treatment compared to the
control group, respectively (n = 4; P > 0.05) as shown in
Figure 6. However, in Figure 6A, sunitinib at 1 μmol/L sig-
nificantly increased the expression of Notch-1 at 24, 48,
and 72 hours of the treatment compared to the control
group, respectively (n = 4; P < 0.01), in which the densi-
tometry ratio of Notch1/β-actin in sunitinib-group was
increased by 2.0-fold, 2.5-fold, and 5.7-fold at 24, 48,
and 72 hours of the treatment compared to the control
group, respectively. The similar results of sunitinib in-
creasing Notch 1expression were also observed in cul-
tured MDA-MB-231 cells (Figure 6B). Interestingly,sunitinib at 1 μmol/L significantly increases the expres-
sion of Notch-1 in cultured MDA-MB-468 and MDA-
MB-231 cells, which may be associated with increasing
breast CSCs.Discussion
The major new findings from this study include: 1) VEGF
is highly expressed in basal-like breast cancer cells (MDA-
MB-468); 2) sunitinib significantly inhibits the prolifera-
tion, invasion, and apoptosis resistance in cultured basal
like breast cancer cells; 3) sunitinib significantly reduces
tumor volume of basal like breast cancer in nude mice in
association with the inhibition of tumor angiogeneisis; 4)
sunitinib increases breast cancer stem cells in vivo; and 5)
sunitinib significantly increases the expression of Notch1
in cultured MDA-MB-468 cells. Though sunitinib inhibits
the progression of basal-like breast cancer by directly tar-
geting both tumor cells and vasculature the possibility
should be considered that it may increase breast cancer
stem cells. In addition, the present studies confirm the
previous report that sunitinib inhibited tumor angiogen-
esis and growth in claudin-low TNBC (MDA-MB-231) xe-
nografts, but increased percentage of breast cancer stem
cells [17].
Figure 6 Western blot analysis indicated that sunitinib at 1 μmol/L significantly increased the expression of Notch-1 at 24, 48, and
72 hours of the treatment in cultured MDA-MB-468 cells (A) and MDA-MB-231 cells (B), respectively. In cultured MDA-MB-468 cells,
compared to the control group, respectively (n = 4; P < 0.01), in which the densitometry ratio of Notch1/β-actin in sunitinib-group was significantly
(P < 0.01) increased by 2.0-fold, 2.5-fold, and 5.7-fold at 24, 48, and 72 hours than the control group, respectively. But, sunitinib at 0.1 μmol/L had no
effect on the expression of Notch-1. The similar results were also observed in cultured MDA-MB-231 cells.
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low molecular subtypes. The majority of TNBCs (ap-
proximately 80%) are the basal-like breast cancers [4].
Also, 12% of the TNBC patients (16/132) have claudin-
low (normal-like) subtype [34]. The basal-like breast
cancer subtype is best identified by DNA microarray ex-
pression profiling, but this methodology is not readily
available in clinical practice [35]. In a phase II study of
patients with heavily pretreated metastatic breast cancer,
15% of patients (three of 20) with TNBC achieved partial
responses following treatment with single-agent suniti-
nib [18]. It is not clinically know whether sunitinib is ef-
fective in the basal or claudin-low molecular subtypes.
Previous studies [17,36,37] showed that sunitinb alone
significantly inhibited tumor growth in the claudin-low
TNBC (MDA-MB-231) xenografts. The present study
demonstrates that the treatment with single-agent suni-
tinib is very effective in the inhibition of the basal-like
breast cancer progression by directly targeting both of
tumor cells and tumor vasculature using MDA-MB-468
xenografts and cultured cells. These findings combined
with the data of sunitinib on MDA-MB-231 xenograftssuggest that sunitinib is effective in the treatment of
TNBCs including the basal and claudin-low molecular
subtypes.
VEGF has been shown to be highly expressed in breast
tumors at levels that are 7-fold higher than normal adja-
cent tissue [38]. The median level of intratumoral VEGF
expression in the TNBC population is significantly
higher than the non-TNBC population (8.2 vs. 2.7 pg/μg
DNA; P < 0.01), in which TNBC patients have a signifi-
cantly worse relapse free survival, earlier distant recur-
rences, and a shorter time between relapse and death,
compared with the non-TNBC group [39]. Although the
median values for VEGF between the TNBC and the
non-TNBC are significantly different, the ranges for both
groups are large [39], implying heterogeneity within the
groups. In the present study, we have found that the
VEGF values are wildly different between cultured MCF-
7 cells (336 ± 15 pg/mg), MDA-MB-231 cells (3408 ±
212 pg/mg), and MDA-MB-468 cells (10257 ± 136 pg/
mg). Even within different TNBC cell lines, the VEGF
values in basal-like (MDA-MB-468) cells are 3-fold higher
than claudin-low (MDA-MB-231) cells. The potential role
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tice remains unclear; however, VEGF has emerged as a
potential therapeutic target in a number of solid malig-
nancies, including breast cancer. High levels of VEGF
expression have been associated with poor clinical out-
come in many solid tumors [39,40]. We assume that su-
nitinib could be more sensitive to the breast tumors
with highly expressed VEGF than the breast tumors
with low expressed VEGF. In the future, we will com-
pare the different responses to sunitinib in treating
breast cancer using MCF-7, MDA-MB-231, and MDA-
MB-468 xenografts.
The in vivo and in vitro findings from this study suggest
that sunitinib targets the basal-like breast cancer tumor
vasculature as well as the tumor epithelial cells directly.
The signal-transduction pathways involving vascular
endothelial growth factor receptor (VEGFR), platelet-
derived growth factor receptor (PDGFR), stem-cell factor
receptor (KIT), and colony stimulating factor-1 receptor
(CSF-1R) have been implicated in breast cancer pathogen-
esis [5-10]. VEGFR and KIT have shown to be associated
with TNBCs [10-13]. Sunitinib is an inhibitor of receptor
tyrosine kinases that include VEGFR, PDGFR, KIT, and
CSF1R [6,11,14]. Though it is possible to antagonize
VEGFR by sunitinib, targeting of other receptors may con-
tribute to the activity of the agent. Preclinical studies
across multiple cell lines have demonstrated IC50 values
in the nanomolar range for c-kit, flt3 and RET [41]. Thus,
VEGFR antagonism alone may not fully explain the anti-
tumor effect of sunitinib.
In the present study, oral sunitinib at 80 mg/kg/2 days
for 4 weeks very significantly inhibits tumor growth in the
basal-like TNBC (MDA-MB-468) xenografts, but it signifi-
cantly increases the percentage of breast cancer stem cells
(CSC) in the tumors. The connection between reduced
tumor angiogenesis/tumor growth, and increased CSC by
sunitinib is of interest. These findings support the notions:
1) antiangiogenic therapies in breast cancer show some
therapeutic potential with increased disease-free survival;
and 2) these initial promising results are short lived and
followed by tumor progression, regrowth, and more ag-
gressive and invasive tumors [42]. CSCs are thought to
play a role in recurrence and metastasis of TNBC [25].
CSCs are predicted to be the cell origin of the tumor and
responsible for tumor progression, relapse and metastasis
due to their self-renewal capacity and limitless prolifera-
tive potential, as well as invasion and migration capacity
[43]. Although CSCs comprise a small amount of the cells
within a tumor, they can be resistant to radiotherapy and
chemo-therapeutic agents, probably because of their qui-
escence. Therefore, the development of successful cancer
therapy requires targeting the CSCs. We would like to de-
velop the TNBC therapeutic regimen with sunitinib plus
anti-CSC agent.Increased CSC by sunitinib is possibly due to increased
intratumoral hypoxia that has been linked to the stimula-
tion of cancer stem cells (CSC) [23,24]. Hypoxia-inducible
factor-1 (HIF-1) has been implicated in the maintenance
of cancer stem cells, although the specific HIF target genes
involved in this process have not been identified [17,44].
Our data on increased CSC by sunitinib in the basal-like
TNBC (MDA-MB-468) xenografts support the previous
findings that antiangiogenic agents increase breast cancer
stem cells via the generation of tumor hypoxia [17].
In studies of stem and/or progenitor cells isolated
from the mammary gland, Notch pathway has been im-
plicated in self-renewal of stem cells, maintaining stem
cell potential and inhibition of differentiation [25]. The
experiments support that the Notch pathway is critical
in controlling the fate of CSC in breast cancer [25,26].
Higher expression of Notch-1 and its ligand Jagged-1 is
associated with poor prognosis in breast cancer [33].
Moreover, studies have suggested that Notch-1 could
play a key role in the regulation of EMT and CSC
phenotype during the development and progression of
tumors [45,46]. The present study shows a new finding
that sunitinib significantly increases the expression of
Notch-1 in culture MDA-MB-468 cells as well as MDA-
MB-231 cells even under the normoxia condition, which
is consistent with increased CSC by sunitinib in the
basal-like TNBC (MDA-MB-468) or the claudin-low
TNBC xenografts. These results support the hypothesis
that the anti-angiogenic therapy may actually activate
Notch and preserve CSC [27]. The further studies are
necessary to investigate the mechanisms of sunitinib-
induced up-regulation of Notch-1. However, sunitinib
plus γ-secretase inhibitor (Notch inhibition) in breast
cancer therapy could be the innovative therapeutic strat-
egies that simultaneously target angiogenesis and CSC.
Conclusion
In conclusion, our results indicate that oral administra-
tion of sunitinib, an inhibitor of receptor tyrosine ki-
nases that include VEGFR, PDGFR, KIT, and CSF1R,
significantly inhibits tumor growth and tumor angiogen-
esis in basal-like TNBC (MDA-MB-468) or claudin-low
TNBC (MDA-MB-231) xenografts that highly express
VEGF. Sunitinib also directly targets the tumor epithelial
cells inhibiting proliferation and migration, and increas-
ing apoptosis. Increased breast cancer stem cells by suni-
tinib in vivo are possibly due to increased intratumoral
hypoxia and the up-regulation of Notch pathway. These
findings suggest that sunitinib alone is effective but not
good enough for treading TNBC. On the other hand, in
combination with the results of sunitinib-increased
CSCs and Notch-1 expression, this work provides the
framework for development of innovative therapeutic
strategies in TNBC therapy by using sunitinib plus γ-
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and CSC. Further studies are necessary to investigate how
combination therapy may improve TNBC treatment.
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